Clear Perspective Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Clear Perspective Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-565	Closed	-$81K	–	173
2019 Q2	$81K	Buy	+565	New	+$75.9K	0.05%	149
2018 Q3	–	Sell	-565	Closed	-$97K	–	290
2018 Q2	$97K	Hold	565	–	–	0.07%	193
2018 Q1	$85K	Hold	565	–	–	0.06%	203
2017 Q4	$76K	Hold	565	–	–	0.06%	208
2017 Q3	$83K	Hold	565	–	–	0.07%	197
2017 Q2	$88K	Hold	565	–	–	0.07%	178
2017 Q1	$82K	Hold	565	–	–	0.05%	174
2016 Q4	$62K	Buy	+565	New	+$62.9K	0.04%	187

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Clear Perspective Advisors's JAZZ Position: Q3 2019 in Review

Clear Perspective Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 565 shares — an estimated $81K sold.

Clear Perspective Advisors first reported a position in JAZZ in Q4 2016 and held it in 8 quarters. The position peaked at $97K in Q2 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

Clear Perspective Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Clear Perspective Advisors sold 565 Jazz Pharmaceuticals shares in Q3 2019, an estimated $81K.
Clear Perspective Advisors first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 8 quarters.
Clear Perspective Advisors's Jazz Pharmaceuticals position peaked at $97K in Q2 2018.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Clear Perspective Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.